290 related articles for article (PubMed ID: 23148736)
1. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.
Kollef MH; Chastre J; Clavel M; Restrepo MI; Michiels B; Kaniga K; Cirillo I; Kimko H; Redman R
Crit Care; 2012 Nov; 16(6):R218. PubMed ID: 23148736
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
Chastre J; Wunderink R; Prokocimer P; Lee M; Kaniga K; Friedland I
Crit Care Med; 2008 Apr; 36(4):1089-96. PubMed ID: 18379232
[TBL] [Abstract][Full Text] [Related]
3. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia.
Merchant S; Gast C; Nathwani D; Lee M; Quintana A; Ketter N; Friedland I; Ingham M
Clin Ther; 2008 Apr; 30(4):717-33. PubMed ID: 18498921
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia.
Zilberberg MD; Mody SH; Chen J; Shorr AF
Surg Infect (Larchmt); 2010 Oct; 11(5):409-17. PubMed ID: 20666580
[TBL] [Abstract][Full Text] [Related]
5. Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.
Kollef MH; Nathwani D; Merchant S; Gast C; Quintana A; Ketter N
Crit Care; 2010; 14(3):R84. PubMed ID: 20459721
[TBL] [Abstract][Full Text] [Related]
6. Antibiotics for ventilator-associated pneumonia.
Arthur LE; Kizor RS; Selim AG; van Driel ML; Seoane L
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD004267. PubMed ID: 27763732
[TBL] [Abstract][Full Text] [Related]
7. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.
Luyt CE; Aubry A; Lu Q; Micaelo M; Bréchot N; Brossier F; Brisson H; Rouby JJ; Trouillet JL; Combes A; Jarlier V; Chastre J
Antimicrob Agents Chemother; 2014; 58(3):1372-80. PubMed ID: 24342638
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator.
Tazuma S; Igarashi Y; Inui K; Ohara H; Tsuyuguchi T; Ryozawa S;
J Gastroenterol; 2015 Feb; 50(2):221-9. PubMed ID: 24795092
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
Freire AT; Melnyk V; Kim MJ; Datsenko O; Dzyublik O; Glumcher F; Chuang YC; Maroko RT; Dukart G; Cooper CA; Korth-Bradley JM; Dartois N; Gandjini H;
Diagn Microbiol Infect Dis; 2010 Oct; 68(2):140-51. PubMed ID: 20846586
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
[TBL] [Abstract][Full Text] [Related]
11. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.
Fink MP; Snydman DR; Niederman MS; Leeper KV; Johnson RH; Heard SO; Wunderink RG; Caldwell JW; Schentag JJ; Siami GA
Antimicrob Agents Chemother; 1994 Mar; 38(3):547-57. PubMed ID: 8203853
[TBL] [Abstract][Full Text] [Related]
12. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.
West M; Boulanger BR; Fogarty C; Tennenberg A; Wiesinger B; Oross M; Wu SC; Fowler C; Morgan N; Kahn JB
Clin Ther; 2003 Feb; 25(2):485-506. PubMed ID: 12749509
[TBL] [Abstract][Full Text] [Related]
13. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.
Ramirez J; Dartois N; Gandjini H; Yan JL; Korth-Bradley J; McGovern PC
Antimicrob Agents Chemother; 2013 Apr; 57(4):1756-62. PubMed ID: 23357775
[TBL] [Abstract][Full Text] [Related]
15. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
16. Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia.
McGarry LJ; Merchant S; Nathwani D; Pawar V; DeLong K; Thompson D; Akhras K; Ingham M; Weinstein MC
J Med Econ; 2010 Mar; 13(1):142-7. PubMed ID: 20136579
[TBL] [Abstract][Full Text] [Related]
17. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
18. A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study).
Mustafa M; Chan WM; Lee C; Harijanto E; Loo CM; Van Kinh N; Anh ND; Garcia J
Int J Antimicrob Agents; 2014 Apr; 43(4):353-60. PubMed ID: 24636429
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
Réa-Neto A; Niederman M; Lobo SM; Schroeder E; Lee M; Kaniga K; Ketter N; Prokocimer P; Friedland I
Curr Med Res Opin; 2008 Jul; 24(7):2113-26. PubMed ID: 18549664
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection.
Singh KP; Li G; Mitrani-Gold FS; Kurtinecz M; Wetherington J; Tomayko JF; Mundy LM
Antimicrob Agents Chemother; 2013 Nov; 57(11):5284-90. PubMed ID: 23939900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
